Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis

ZUG, Switzerland, March 31, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced that its neuroprotective candidate Privosegtor has been granted Priority Medicines (PRIME) designation by the European Medicines Agency (EMA) for the treatment of optic neuritis (ON), a rare, sight-threatening condition that is often a relapse of multiple sclerosis or its first clinical manifestation.